Jump to main content


Penelope, GATTEX patient
with her mom, Kelsey

GATTEX® (teduglutide) is a prescription medicine used in adults and children 1 year of age and older with short bowel syndrome (SBS) who are dependent on parenteral support (PS)

The science behind GATTEX

GATTEX works like a natural GLP-2.

In a study of adults, GATTEX was proven to help the remaining intestine absorb more fluid.*

Increased absorption of fluid by the intestines by ~750 to 1000 mL/day

villus height

increased depth
between villi

The image above is for illustrative purpose only.

The ability of GATTEX to improve the amount of fluid absorbed by the intestines was studied in 17 adults with SBS. Participants in the study received GATTEX for 21 days. All the participants in this study knew they were taking GATTEX. They each took daily doses of either 0.03, 0.10, or 0.15 mg/kg by injection (0.6 to 3 times the recommended dose). The recommended dose is 0.05 mg/kg/day. The injections were administered under the skin in the stomach area (abdomen). All of the doses studied, except for the 0.03 mg/kg once-daily dose, resulted in enhanced absorption of fluid by the intestines—approximately 750 to 1000 mL per day—and increased the surface area of the intestines.

The ability of GATTEX to improve intestinal absorption in children has not been investigated.

Understanding How GATTEX Works

Watch this video to gain a better understanding of short bowel syndrome and the GATTEX mechanism of action.

Gattex is the first and only medicine that works like the
glp-2 the body normally makes on its own

See the results of the clinical trials in patients on PS

Common Side Effects of GATTEX

In clinical studies of adults, the most common (≥10%) side effects were:

  • Stomach area (abdomen) pain or swelling
  • Nausea
  • Cold or flu symptoms
  • Skin reaction where the injection was given
  • Vomiting
  • Swelling of the hands or feet
  • Allergic reactions

Work with your child's doctor to understand treatment expectations and check with them if your child is experiencing any side effects. Have your child continue taking GATTEX as long as their doctor recommends.

The safety of GATTEX has been studied in 41 children with short bowel syndrome (SBS) across 2 clinical studies‖‖

The side effects seen in children and adolescents (aged 1 to 17 years) were similar to those seen in adults. Be sure to talk to your or your child’s doctor about any side effects that are bothersome or that do not go away.

‖‖This includes pediatric patients from an additional 3-month study that was conducted with GATTEX.


I had no expectations...
but we kept going...
Penelope’s now free from PS

mother of Penelope,
GATTEX patient

After 6 months of treatment, 3 out of 26 children treated
with GATTEX no longer needed PS.
Individual results may vary.

“I had no expectations... but we kept going... Penelope’s now free from PS”


After 6 months of treatment, 3 out of 26 children treated with GATTEX no longer needed PS.
Individual results may vary

Things to keep in mind during your child’s treatment journey

Track your child’s experiences and keep detailed notes that can be used in conversations with the doctor.

Check in with the doctor and talk openly about what your child is experiencing.

Take GATTEX as recommended by your child's doctor.

Everyone with sbs is unique. Experiences with gattex will be, too.

Considering GATTEX?

Download our helpful Treatment Tracker or see what goes into getting started

Getting started

Stay informed and connected

Sign up to receive ongoing updates and communications about upcoming events, treatment information, education, resources, and market research opportunities.

*First name is required
*Last name is required
*Email address is required
*Zip Code is required

Do you or someone you care for have SBS?*

Select one
*Please select an option

Age of Person Experiencing Bowel Problems*


*Please select an option

All fields marked with * are required.

Please see our online privacy notice for information about our practices regarding collection, use, and disclosure of information that you may provide us.